KRAS and neoplasm: The KRAS gene can simultaneously harbor multiple mutations that can potentiate tumor-promoting activity in several human cancers; thus, it is necessary to utilize a new therapeutic strategy to inhibit this oncoprotein and therefore the development of cancer (Mustachio et al., 2021).